An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Participants

In brief

The purpose of this study is to evaluate the effects of the experimental medication BMS-986256 in healthy participants.

Key facts

Study ID

NCT03634995

Run by

Bristol-Myers Squibb

People needed

118

Starts

2018-08-14

Expected to finish

2019-10-09

Last updated by the study team

2020-06-16

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Weight ≥ 50 kg and body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive at screening
• Participants must not be current users (within 6 months before screening) of tobacco or tobacco- or nicotine-containing products; they must also be willing to refrain from using any of these products during their participation in the study
• A negative QuantiFERON®-TB Gold test result at screening or documentation of a negative result within 3 months before screening

You may not qualify if…

• Previous participation in the current study or previous exposure within 6 weeks before study drug administration for non-biologics and 12 weeks before study drug administration for biologics
• Inability to tolerate oral medication
• Inability to tolerate venipuncture, or inadequate venous access
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Anaheim Clinical Trials — Anaheim, California, United States
• PRA Health Science KK — Lenexa, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.